The Starfish Project

The combined effort of our whole family.

Intravenous Ascorbate as a Chemotherapeutic Agent

leave a comment »

Case histories
We have seen patients with almost every type of solid tumor in our center. Many of them have received IAA (intravenous ascorbic acid), with various degrees of success. Our cases include a patient with cancer of the head of the pancreas who lived for 3.5 years with IAA as sole therapy, resolution of bone metastases in patients with breast cancer, many patients with non-Hodgkin’s lymphoma (none of whom have died from their disease), resolution of primary liver carcinoma tumors, resolution of and reduction in size of metastatic colon carcinoma lesions, and resolution of metastatic lesions and over 3-year survival in patients with widely metastatic ovarian carcinoma. We plan to present a full compilation of cases in another communication.

We have seen only two cases of metastatic renal cell carcinoma, considered a uniformly untreatable disease. Because the results were so dramatic, people with this disease could potentially benefit the most from IAA treatment. Following are those two cases.

Case 1
A 52-year-old white female with a history of renal cell carcinoma was seen in our center for the first time in October, 1996.

In September 1995, shortly after diagnosis of a primary tumor in her left kidney, a nephrectomy was performed. Histology confirmed renal cell carcinoma. No evidence of metastases was found at that time. In March 1996, metastases to the lungs were found on chest x-ray film. In September 1996, a chest x-ray film revealed 4 1- to 3-cm masses in her lungs. One month later there were 8 1- to 3-cm masses in her lungs (7 in right lung, 1 in left).

No new medical, radiation, or surgical therapies were performed prior to her visit to our clinic in October 1996, when she began IAA therapy. Her initial dose was 15 g, which increased to 65 g after 2 weeks, two per week. She was also started on: N-acetyl cysteine (Vitamin Research Products, Carson City, NV), 500 mg 1 p.o., QD; beta-1,3- glucan (a macrophage stimulator, NSC-24, Nutrition Supply Corp., Carson City, NV), 2.5 mg 3 p.o. QD; fish oil (Super-EPA, Bronson Pharmaceuticals, St. Louis, MO; 300 mg eicosatetraenoic acid, 200 mg docosahexaenoic acid), 1 p.o. TID; vitamin C, 9 g p.o. QD; beta-carotene (Beta Carotene 25, Miller Pharmacal Group, Inc., Carol Stream, IL), 25,000 lU. 1 p.o. BID; L-threonine (The Solgar Vitamin Co, Inc., Lynbrook, NY), 500 mg p.o. QD (for a deficiency revealed by laboratory testing of serum); Bacillus laterosporus (Lateroflora, International Bio-Tech U.S.A., San Marcos, CA), 280 mg, 2 p.o. QD for intestinal Candida albicans, inositol hexaniacinate complex (Niaplex, Karuna Corp., Novato, CA; 500 mg niacin, 100 mcg chromium) 2 p.o. QD, and a no-refined-sugar diet.

She continued IAA treatments until June 1997 when another chest x-ray film revealed resolution of 7 of the 8 masses, and reduction in the size of the 8th. According to the medical imaging report, “The nodular infiltrates seen previously in the right lung and overlying the heart are no longer evident and the nodular infiltrate seen in left upper lung field has shown marked interval decrease in size and only vague suggestion of an approximately 1 cm density.”

The patient discontinued IAA treatments in June 1997. She has continued on an oral nutritional support program since that time, and 4 years later was well with no evidence of progression.

Case 2
In December 1985, a mass occupying the lower pole of the right kidney was discovered in a 70-year-old white male. Pathology of the mass after a radical nephrectomy confirmed renal cell carcinoma. He was followed by an oncologist at another clinic. Approximately three months after surgery, the patient’s x-ray film and CT scan showed “multiple pulmonary lesions and lesions in several areas of his liver which were abnormal and periaortic lymphadenopathy.”

In March 1986 the patient was seen in our clinic (1). He decided not to undergo chemotherapy. He requested and was started on IAA, 30 g twice per week.

In April 1986, six weeks after the x-ray film and CT scan studies, the oncologist’s report stated,

“. . . the patient returns feeling well. His exam is totally normal. His chest x-ray shows a dramatic improvement in pulmonary nodules compared to six weeks ago. The periaortic lymphadenopathy is completely resolved… either he has had a viral infection with pulmonary lesions with lymphadenopathy that has resolved or (2) he really did have recurrent kidney cancer which is responding to your vitamin C therapy.”
The oncology report in July 1996 stated, “there is no evidence of progressive cancer. He looks well . . . chest x-ray today is totally normal. The pulmonary nodules are completely gone. There is no evidence of lung metastasis, liver metastasis or lymph node metastasis today, whatsoever.”

In 1986 the patient received 30 g infusions twice-weekly for 7 months. The treatments were then reduced to once per week for 8 more months. For an additional 6 months he received weekly, 15 g IAA infusions.

During and after treatments, the patient reported no toxicities, and his blood chemistry profiles and urine studies were normal.

The patient continued well, and was seen periodically at our clinic until early 1997 when he died, cancer-free, at age 82, 12 years after diagnosis.

Now, our standard approach uses initial infusions of 15, 25 and 50 grams. This allows projecting the dose needed to achieve cytotoxicity.

Source:  BrightSpot.org

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: